ECHA Adds 3 PCR Plastic Restricted Substances

Time : Jun 27, 2026

On June 26, 2026, the European Chemicals Agency (ECHA) introduced an immediate compliance change affecting recycled plastic exports into the EU market. The update places three substances under a non-detectable requirement for post-consumer recycled (PCR) plastics and applies to packaging, automotive interior materials, and electronic housings containing PCR content. For exporters, the change is not limited to substance control alone; it also adds a document-timing requirement, as EU customers must receive updated batch test reports and substance declarations issued by ISO/IEC 17025 accredited laboratories. This matters because it directly touches shipment readiness, customer documentation, supplier coordination, and acceptance risk across several parts of the supply chain.

ECHA Adds 3 PCR Plastic Restricted Substances

What the June 26 update confirms

According to the provided event information, ECHA urgently updated REACH Annex XVII on June 26, 2026. The update adds dicyclohexyl phthalate (DCHP), tris(2-chloroethyl) phosphate (TCEP), and derivatives of perfluorooctanoic acid (PFOA) to the list of substances that must not be detected in PCR plastics.

The scope stated in the event summary covers all materials containing PCR content used in packaging, automotive interior applications, and electronic outer casings. The rule took effect immediately on the same day.

The same event summary also states that exporters must provide EU customers with the latest batch testing report and a substance declaration. Those documents must be issued by laboratories accredited to ISO/IEC 17025.

Where the pressure will show up first

Export shipments may face a faster documentation cycle

From an industry perspective, exporters are likely to feel the change first because the rule links market access expectations to both testing and documentation. The practical impact is likely to appear in pre-shipment review, customer release procedures, and document handover timing. What deserves closer attention is whether current export files for PCR-containing products already include batch-specific reports and declarations in a form acceptable to EU customers.

Procurement teams will need closer visibility into PCR inputs

Analysis shows that raw material buyers and sourcing teams may be affected because the restricted-substance requirement is tied to PCR content itself. In practice, procurement decisions may need to place more weight on upstream material traceability, supplier declarations, and the availability of current testing evidence for each batch. This is less about broad supplier management and more about whether purchased PCR inputs can support compliant downstream documentation.

Manufacturers may see changes in release and delivery coordination

Manufacturing companies producing packaging, automotive interior parts, or electronic housings may encounter pressure at the point where production release meets customer compliance review. Observably, the issue is not only whether a material formulation is acceptable, but whether the related batch documentation can move in step with delivery schedules. Where documentation lags, delivery confirmation, customer acceptance, or internal release approval may become more difficult.

Testing and compliance service providers may become part of the delivery path

Laboratories and compliance support providers may also become more central to execution because the event summary specifically requires reports from ISO/IEC 17025 accredited laboratories. From an industry perspective, this means testing capacity, report turnaround, and document consistency could become operational issues for companies serving EU-bound PCR products, especially where customers expect updated records within a short window.

What companies should review immediately

Check whether current files match the new batch-based expectation

Analysis shows that companies handling affected PCR materials should first review whether their existing compliance files are current by batch and ready for customer submission. The event summary refers to the latest batch test report and substance declaration, so older general statements or non-batch-specific records may deserve closer scrutiny.

Reconfirm laboratory and declaration pathways

What deserves closer attention is the document chain behind each shipment. Companies may need to verify whether their testing reports are issued by ISO/IEC 17025 accredited laboratories and whether internal or supplier-issued substance declarations are aligned with the same batch and product scope. This is a document-control issue as much as a material-control issue.

Review contracts, customer requests, and tender language

Observably, the rule change may begin to appear in customer purchasing terms, incoming compliance questionnaires, and technical document requests. Businesses supplying affected product categories may need to monitor whether buyers revise specification files, quality annexes, or shipment release conditions to reflect the new ECHA update.

Watch execution details that are not yet described in the input

Analysis shows that several practical questions still require attention, including how customers interpret documentation timing, how strictly they align declarations with each batch, and whether additional supporting records will be requested in practice. Because the input does not provide those execution details, it is more appropriate to treat them as follow-up points for ongoing monitoring rather than confirmed requirements.

Why this looks like an execution signal, not a distant policy trend

Observably, this update is better understood as an already effective compliance signal rather than a long-horizon policy discussion. The immediate effective date and the requirement to provide updated testing and declaration documents indicate that the issue has moved into operational execution. At the same time, analysis shows that the market still needs to watch how customers, testing partners, and supply-chain participants translate the rule into daily document checks, release conditions, and acceptance practice.

How the market is likely to read this development

From an industry perspective, the most reasonable reading is that the compliance threshold for PCR-containing products entering EU-facing supply chains has become more document-sensitive and batch-sensitive at the same time. The confirmed facts point to a rule already in force, but the full commercial impact will depend on how consistently the new requirement is reflected in procurement files, testing workflows, customer requests, and delivery approvals. It is more appropriate to understand this as a live compliance change with immediate operational implications and with further execution details still worth watching.

Basis of this article and what still needs verification

This article is based on the user-provided news title, event date, and event summary. For developments of this kind, source categories typically relevant to verification include official notices, releases from regulatory authorities, trade or customs authority information, industry association updates, standard-setting documents, and reporting by authoritative media. A specific official source link was not provided in the input, so the exact official publication path still needs to be verified on an ongoing basis.

Observably, the areas that still require continued follow-up include any further official wording, certification or testing implementation practices, customer-side document requirements, tender or specification updates, market feedback, and the way affected companies actually execute the new requirement in shipment and compliance workflows.

Have questions about this sector analysis, or seeking best practices specific to your niche? Drop us a line below and let the senior consultants at APIM assist you.

Submit

We respect your privacy. Your information is strictly confidential.